Trump said he doesn't see a recession after the bond market spooked investors and the Dow suffered its worst day of the year last week.Marketsread more
Americans now say they approve of free trade by 64%-27%, a margin of better than two to one. That's up from 57%-37% early in Trump's presidency, and 51%-41% near the end of...Politicsread more
Stocks in Asia edged up Monday morning as U.S. Treasury yields bounced higher after plunging last week which sent markets into a panic.Asia Marketsread more
Beijing wants to use reforms to support a slowing economy.China Marketsread more
Trump said Cook made a "good case" that it would be difficult for Apple to pay tariffs, when Samsung does not face the same hurdle because much of its manufacturing is in...Technologyread more
The yield on the benchmark 10-year Treasury note briefly fell below the 2-year rate on Wednesday, a phenomenon in the bond market known as yield curve inversion, which is...Marketsread more
Despite aggressive strides, Waymo needs one thing before their self-driving cars become a seriously useful transportation system: people. We talked to the ones closest to it.Technologyread more
"I don't want to do business at all because it is a national security threat," Trump told reporters.Technologyread more
Trump's is due to visit Copenhagen early next month, when the Arctic will be on the agenda in meetings.Europe Politicsread more
The MacBook Pro recall and its subsequent ban from flights underscores the increasing brand risk from problems with lithium-ion batteries.Technologyread more
Experts say the timing of Amazon executives' contributions to Rep. David Cicilline likely reflect the company's heightened urgency over growing regulatory scrutiny.Technologyread more
The biopharmaceutical company Juno Therapeutics was given the green light to resume a crucial clinical trial Tuesday, less than a week after federal health regulators halted the phase 2 study on a potential cancer treatment on the heels of two patients dying.
Juno's shares has plummeted last Friday by more than 30 percent after the U.S. Food and Drug Administration imposed the clinical hold on the trial that day.
In the wake of Tuesday's news, Juno shares traded up more than 24 percent in after-hour trading.
Juno had disclosed last Thursday that two people in the trial had died after the company added the chemotherapy drug fludarabine to the regimen in the trial, which involves adult patients with relapsed or refractory B cell acute lymphoblastic leukemia. The trial is known as the "ROCKET" trial.
The treatment is Juno's most advance drug candidate. After the hold was imposed, JPMorgan reduced its price target for Juno shares to $39 from $63, while FBR Capital Markets lower its price target to $61 from $73.
The FDA last week requested that Juno submit a complete response to the hold, which would require the company to revise several documents including its informed consent form and trial protocol.
Under the revised protocol, the ROCKET trial will continue enrollment using JCAR015 with cyclophosphamide pre-conditioning only, the company said.